PhoreMost Collaborates with Polaris and NeoCura on Cancer Therapeutics

Published on: 
BP Elements, BioPharm International's BP Elements, February 2022, Volume 1, Issue 2

PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.

PhoreMost, a UK-based biopharmaceutical company, has formed separate partnerships with Polaris Quantum Biotech (POLARISqb), a US-based quantum computing drug design company, and NeoCura Bio-Medical Technology (NeoCura), an RNA-based drug research and development company headquartered in China, to study and discover new oncology therapies.

The POLARISqb Tachyon quantum computing platform will be used to scan billions of molecules from a large chemical space to find novel molecules that can be developed into drugs, based on information obtained from PhoreMost’s SITESEEKER phenotypic screening platform, a novel target-identification platform, according to PhoreMost in a Jan. 5, 2022, company press release.

SITESEEKER rapidly identifies unexpected or “cryptic” druggable sites across an entire genome, and PhoreMost, in collaboration with POLARISqb, will use the platform to identify oncology targets previously considered undruggable. This identification will be conducted using the inherent shape diversity and disease functionality of the PROTEINi (based on protein interference) protein-fragment libraries in live cells.

POLARISqb has built a drug discovery platform using Tachyon, a quantum computer that has the potential to significantly shorten the drug discovery process, according to the press release. With the use of quantum computers, POLARISqb can perform combinatorial optimizations in minutes that would take conventional supercomputers months or years to complete. The use of quantum computers leads to reduced drug development timelines and more efficient research, PhoreMost stated in the press release.

“This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI [artificial intelligence] is going to be an exciting and transformative milestone for the entire pharmaceutical industry,” said Chris Torrance, CEO, PhoreMost, in the press release.


Under the NeoCura collaboration, PhoreMost will use its SITESEEKER platform together with NeoCura’s full-process RNA drug design platform to investigate the cellular delivery and efficacy of encoded targeted peptides. This research aims to inform and advance the research and development of innovative anti-cancer therapies.

“It is believed that with the … RNA drug research and development capability of NeoCura and … SITESEEKER technology of PhoreMost, more therapeutic potential will be released in the field of research and development of RNA drugs, and the translational process of anti-cancer drugs will be greatly accelerated. Meanwhile, NeoCura also hopes to join hands with more industry leaders in the vigorous development of biomedicine in China,” said Wang Yi, founder and CEO of NeoCura, in a Jan. 11, 2022, press release.

“NeoCura’s platform complements PhoreMost’s capabilities to unmask cryptic druggable sites across the entire human proteome. RNA delivery of novel therapeutics represents an exciting opportunity for PhoreMost as we aim to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases,” said Torrance in the press release.

Source: PhoreMost for POLARISqb announcement and for NeoCura announcement